ABSTRACT

There is provided a T-type calcium channel blocker that is a compound of formula (1), a pharmaceutically acceptable salt thereof or a solvate thereof:



(1)

wherein

Ar^1 is phenyl group, pyridyl group, furyl group or 2,1,3-benzoxadiazol-4-yl group;

nitrogen-containing hetero ring moiety is 1,4-dihydropyridine ring or pyridine ring;

Z is a group of formula (2)

(2)

or CO_2R^2;

R^a and R^b are independently of each other $C_{1\text{-}6}$alkyl group, ANR^8R^9, $CH_2OANR^8R^9$, or the like;

in case where the nitrogen-containing hetero ring moiety is 1,4-dihydropyridine ring, R^1 is $C_{1\text{-}6}$alkyl group, ANR^8R^9, $AN(CH_2CH_2)_2NR^8$, $AN(CH_2CH_2)_2O$, AOR^8 or benzyl group;

R^3 is hydrogen atom, $C_{1\text{-}20}$alkyl group, ANR^8R^9, a group of formula



or the like.